Patents by Inventor Yoko Fukui
Yoko Fukui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230330637Abstract: [Problem] The purpose of the present invention is to provide a deodorizing catalyst that can decompose a malodorous substance even at a low temperature of 100° C. or less. [Solution] A deodorizing catalyst for decomposing a malodorous substance, comprising: manganese oxide wherein the manganese oxide satisfies the following expression (1) and the following expression (2), and the manganese oxide has a maximum intensity peak at a diffraction angle (2?) of 37±1° in an X-ray diffraction pattern: 0<A?0.90 . . . ??(1) 0<B?250 . . .Type: ApplicationFiled: September 2, 2021Publication date: October 19, 2023Applicants: NBC MESHTEC INC., TOKYO METROPOLITAN PUBLIC UNIVERSITY CORPORATION, THE UNIVERSITY OF TOKYOInventors: Yoko FUKUI, Youhei JIKIHARA, Toru MURAYAMA, Tetsuya SHISHIDO, Takashi TAKEI, Mingyue LIN, Haifeng WANG, Kazuya YAMAGUCHI
-
Patent number: 11166974Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.Type: GrantFiled: March 16, 2020Date of Patent: November 9, 2021Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
-
Patent number: 10744351Abstract: A mask is provided that can inactivate viruses adhering thereto even in the presence of lipids and proteins regardless of whether or not the viruses have an envelope. The mask can inactivate viruses adhering thereto and includes a mask body provided with a member used when the mask is worn and virus inactivating fine particles having a virus inactivating ability and held by the mask body. The virus inactivating fine particles are particles of at least one selected from the group consisting of platinum(II) iodide, palladium(II) iodide, silver(I) iodide, copper(I) iodide, and copper(I) thiocyanate.Type: GrantFiled: September 30, 2010Date of Patent: August 18, 2020Assignee: NBC MESHTEC, INC.Inventors: Yoshie Fujimori, Youhei Jikihara, Tetsuya Sato, Yoko Fukui, Tsuruo Nakayama
-
Publication number: 20200215093Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.Type: ApplicationFiled: March 16, 2020Publication date: July 9, 2020Applicant: Santen Pharmaceutical Co., Ltd.Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
-
Patent number: 10632139Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.Type: GrantFiled: August 14, 2018Date of Patent: April 28, 2020Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
-
Publication number: 20180353531Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.Type: ApplicationFiled: August 14, 2018Publication date: December 13, 2018Applicant: Santen Pharmaceutical Co., Ltd.Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
-
Patent number: 10071113Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.Type: GrantFiled: October 10, 2016Date of Patent: September 11, 2018Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
-
Publication number: 20170020910Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.Type: ApplicationFiled: October 10, 2016Publication date: January 26, 2017Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Akiko SAKATANI, Tatsuo IKEI, Koji INAGAKI, Masatsugu NAKAMURA, Kazuhiro HOSOI, Mikiko SAITO, Masaki SONODA, Yoko FUKUI, Mitsuaki KUWANO
-
Publication number: 20160324892Abstract: [Problem] To provide a bactericidal composition for bacterial skin disease against which it is difficult for bacteria that cause bacterial skin disease to acquire drug resistance. [Solution] A bactericidal composition for bacterial skin disease that is characterized by including silver iodide in the form of nanoparticles having a particle size of 1-100 nm, inclusive, iodide ions, a water-soluble polymer, and an organic acid having a carboxyl group, and/or a salt of said acid, wherein the molar ratio of silver to iodide ions in the silver iodide is 1:1-1:1000.Type: ApplicationFiled: February 6, 2015Publication date: November 10, 2016Applicant: NBC MESHTEC INC.Inventors: Yoko FUKUI, Eri MAZUYAMA, Yoshie FUJIMORI, Tomokazu NAGAO, Tsuruo NAKAYAMA
-
Patent number: 9486529Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.Type: GrantFiled: March 25, 2013Date of Patent: November 8, 2016Assignee: SANTEN PHARMCEUTICAL CO., LTD.Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
-
Patent number: 9380785Abstract: To provide an antiviral resin member which can efficiently inactivate viruses and has excellent sustainability. An antiviral resin member comprising a resin, an antiviral agent, and a surface potential-controlling agent, characterized in that the surface potential-controlling agent causes the surface potential of the antiviral resin member to shift to a value on the positive side of the potential of the resin alone.Type: GrantFiled: July 6, 2012Date of Patent: July 5, 2016Assignee: NBC MESHTEC, INC.Inventors: Shinji Kurahashi, Nobukazu Motojima, Yoko Fukui, Tsuruo Nakayama
-
Patent number: 9155309Abstract: A virus inactivating sheet is provided that can inactivate viruses adhering thereto even in the presence of lipids and proteins regardless of whether or not the viruses have an envelope. The virus inactivating sheet can inactivate viruses adhering thereto and includes a sheet body, and monovalent copper compound fine particles and/or iodide fine particles that are held by the sheet body. The virus inactivating sheet can inactivate various viruses. These viruses can be inactivated even in the presence of lipids and proteins.Type: GrantFiled: October 4, 2010Date of Patent: October 13, 2015Assignee: NBC MESHTEC, INC.Inventors: Yoshie Fujimori, Youhei Jikihara, Tetsuya Sato, Yoko Fukui, Tsuruo Nakayama
-
Patent number: 9045855Abstract: Disclosed is an anti-viral member which can inactivate a virus. Specifically disclosed is an anti-viral member which is characterized by comprising a base material, univalent copper compound microparticles, and inorganic microparticles which are provided for the purpose of retaining the univalent copper compound microparticles on the base material and each of which has a silane monomer bound to the surface thereof via a chemical bond, wherein the inorganic microparticles are bound to one another via chemical bonds formed between the silane monomers provided on the surfaces thereof, and each of the inorganic microparticles is bound to the base material via a chemical bond between the silane monomer and the base material to form spaces in which the univalent copper compound microparticles are to be retained.Type: GrantFiled: December 28, 2009Date of Patent: June 2, 2015Assignee: NBC Meshtec, Inc.Inventors: Yoshie Fujimori, Tsuruo Nakayama, Yoko Fukui
-
Publication number: 20150072951Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.Type: ApplicationFiled: March 25, 2013Publication date: March 12, 2015Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
-
Publication number: 20140367263Abstract: [Problem] To provide an anti-virus aluminum member capable of minimizing secondary infection by deactivating viruses in a short period of time even when viruses adhere thereto, regardless of whether a viral envelope is present, and useful for application in door knobs, handrails, air-conditioner fins or the like. [Solution] An anti-virus aluminum member capable of deactivating viruses that adhere thereto is characterized in that an anti-virus inorganic compound is present in the pores of an anodized membrane provided with multiple pores and obtained by anodizing aluminum or an aluminum alloy.Type: ApplicationFiled: September 7, 2012Publication date: December 18, 2014Inventors: Yoko Fukui, Tsuruo Nakayama, Yoshie Fujimori
-
Publication number: 20140221306Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent, formation of insoluble precipitates found in Diquafosol ophthalmic solution during its storage, as well as deterioration of the filtration performance in the course of production (filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, enhancement of preservative effectiveness has been confirmed. Accordingly, the present invention provides Diquafosol ophthalmic solution having physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient. Particularly in the course of production, the solution can be subjected to efficient filtration sterilization. Moreover, the solution has excellent preservative effectiveness.Type: ApplicationFiled: December 27, 2011Publication date: August 7, 2014Applicant: Santen Pharmaceutical Co. LtdInventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
-
Publication number: 20140127321Abstract: To provide an antiviral resin member which can efficiently inactivate viruses and has excellent sustainability. An antiviral resin member comprising a resin, an antiviral agent, and a surface potential-controlling agent, characterized in that the surface potential-controlling agent causes the surface potential of the antiviral resin member to shift to a value on the positive side of the potential of the resin alone.Type: ApplicationFiled: July 6, 2012Publication date: May 8, 2014Applicant: NBC MESHTEC, INC.Inventors: Shinji Kurahashi, Nobukazu Motojima, Yoko Fukui, Tsuruo Nakayama
-
Publication number: 20120192876Abstract: A mask is provided that can inactivate viruses adhering thereto even in the presence of lipids and proteins regardless of whether or not the viruses have an envelope. The mask can inactivate viruses adhering thereto and includes a mask body provided with a member used when the mask is worn and virus inactivating fine particles having a virus inactivating ability and held by the mask body. The virus inactivating fine particles are particles of at least one selected from the group consisting of platinum(II) iodide, palladium(II) iodide, silver(I) iodide, copper(I) iodide, and copper(I) thiocyanate.Type: ApplicationFiled: September 30, 2010Publication date: August 2, 2012Inventors: Yoshie Fujimori, Youhei Jikihara, Tetsuya Sato, Yoko Fukui, Tsuruo Nakayama
-
Publication number: 20120171276Abstract: A virus inactivating sheet is provided that can inactivate viruses adhering thereto even in the presence of lipids and proteins regardless of whether or not the viruses have an envelope. The virus inactivating sheet can inactivate viruses adhering thereto and includes a sheet body, and monovalent copper compound fine particles and/or iodide fine particles that are held by the sheet body. The virus inactivating sheet can inactivate various viruses. These viruses can be inactivated even in the presence of lipids and proteins.Type: ApplicationFiled: October 4, 2010Publication date: July 5, 2012Inventors: Yoshie Fujimori, Youhei Jikihara, Tetsuya Sato, Yoko Fukui, Tsuruo Nakayama
-
Publication number: 20110262513Abstract: Disclosed is an anti-viral member which can inactivate a virus. Specifically disclosed is an anti-viral member which is characterized by comprising a base material, univalent copper compound microparticles, and inorganic microparticles which are provided for the purpose of retaining the univalent copper compound microparticles on the base material and each of which has a silane monomer bound to the surface thereof via a chemical bond, wherein the inorganic microparticles are bound to one another via chemical bonds formed between the silane monomers provided on the surfaces thereof, and each of the inorganic microparticles is bound to the base material via a chemical bond between the silane monomer and the base material to form spaces in which the univalent copper compound microparticles are to be retained.Type: ApplicationFiled: December 28, 2009Publication date: October 27, 2011Applicant: NBC MESHTEC, INC.Inventors: Yoshie Fujimori, Tsuruo Nakayama, Yoko Fukui